Prostate cancer is among serious health issue among men has large socioeconomic impact on the society. It is the most common cancer diagnosed among men in developed regions, while it is sixth most common cancer diagnosed in less developed nations. Routine screening, early diagnosis, and recent treatment options have enabled increased survival of prostate cancer patients. Prostate cancer is an abnormal and uncontrolled growth of cells in prostate gland of a male individual. Approximately 75% of prostate cancers are developed sporadically in which genetic changes occur after birth. Although, cause prostate cancer is largely unknown, some of the prime factors associated with the disease include obesity, overweight and past history of certain cancers. A person with cardiovascular disease is more prone to advanced metastatic cancer.
Androgens have significant role in the pathogenesis of prostate cancer and therefore androgen-deprivation therapy (ADT) was found to be most useful in treating of locally advanced or metastatic prostate cancer. Presently, the prostate cancer therapeutics market is driven by major drugs such as Zytiga (Johnson & Johnson), Xtandi (Astellas Pharma, Inc. / Medivation, Inc.), Provenge (Dendreon Corporation), Jevtana (Sanofi) and Xofigo (Bayer Healthcare Pharmaceutical, Inc.). The prostate cancer therapeutics market is slated to increasing rapidly in the near future owing to promising drugs in the pipeline. These drugs are expected to drive the market during the forecast period from 2015 to 2023. In 2013, Johnson & Johnson acquired Aragon Pharmaceuticals that has second generation androgen receptor signaling inhibitor (ARN-509), a highly potential drug for treatment of castration resistant prostate cancer. This acquisition is seen as a strategic move by Johnson & Johnson to mitigate the expected slowing of Zytiga sales.
Zytiga, launched in 2011, clocked sales of over USD 1 billion in 2012 and works by targeting the enzyme CYP17A1 responsible for androgen production. The drug is expected to lose its patent protection in 2016. Moreover, Zytiga is facing stiff competition from Xtandi (Astellas Pharma, Inc. / Medivation, Inc.). The Astellas’ drug has already matched the sales of Zytiga and is rapidly moving further upstream as the patients are using treatment for long period and urologists continuing to adopt the drug. High prices of newer drugs and uncertain reimbursement policies will be restraining the market to some extent. However, the growing awareness about prostate cancer, rapid urbanization, and government efforts to fund cancer treatment will drive the market during the forecast period from 2015 to 2023.
On the basis of geography, the global prostate cancer therapeutics market can be segmented into four major regions, namely, North America, Europe, Asia Pacific, and Rest of the world. American men have highest rates of prostate cancer followed the European males. It is estimated that more than 230,000 new cases of prostate cancer were diagnosed in the U.S. in 2014. In U.K., more than 40,000 new cases are registered having prostate cancer, and about 11,000 deaths occur annually. Therefore, the global prostate cancer therapeutics market has been traditionally dominated by North America Asia region ranks lowest in terms of rate of prostate cancer.
Some of the key players in this market are Johnson & Johnson, AstraZeneca plc, Astellas Pharma, Inc., Sanofi, Medivation, Inc., Ipsen SA and Bayer Healthcare Pharmaceutical, Inc.
This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. This report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Reasons for Buying this Report
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a six-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.